Corgenix Medical Corp’s wholly owned subsidiary, Corgenix Inc, entered into a contract manufacturing and supply agreement with diaDexus Inc. Under the terms of the five-year agreement, Corgenix will manufacture and supply the PLAC® Test ELISA product for diaDexus.
The PLAC Test measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The American Association of Clinical Endocrinologists (AACE) recently announced the inclusion of Lp-PLA2 in its medical guidelines for clinical practice, an important endorsement of the clinical utility of Lp-PLA2 measurement. Specifically, the guidelines recommend the use of multiple markers, including Lp-PLA2, to assist physicians in personalizing therapy for elevations or other abnormalities in blood lipids. These abnormalities, commonly referred to as "dyslipidemia," are a major risk factor for coronary artery disease.
Corgenix management stated that the new agreement with diaDexus will be an important addition to the company’s contract manufacturing program, contributing meaningful revenues in Fiscal 2013.
Source: Corgenix Medical Corp
